The ^AX12 chip simplifies TEER measurements, enabling easy integration with existing systems. When paired with our TEEROC, it delivers fully automated, robust, and reproducible barrier integrity assessments—saving valuable time.

The platform’s design facilitates straightforward sampling from both apical and basolateral chambers, enabling precise analysis of molecular diffusion and cellular transmigration.

Thanks to its configuration, the ^AX12 platform allows rapid, efficient supernatant collection, ideal for downstream protein and cytokine quantification using ELISA, multiplex immunoassays, or mass spectrometry.

Fully compatible with advanced omics workflows—including transcriptomics, proteomics, and metabolomics—the ^AX12 platform enables comprehensive cellular and molecular profiling in barrier tissue models.

TEER evaluates barrier function and cell layer integrity to investigate gut permeability, , lung EDEMA or drug-induced barrier impairment.
Permeability Assay evaluates on one hand passive transport of a molecule across a cell barrier and therefore barrier-tightness, on the other hand active molecule transport across a barrier. This assay can be used to investigate barrier tightness like TEER or to study in vitro ADME for molecule or drug transport, uptake or delivery.

Live cell imaging allows assessment of cell morphology, cytotoxicity or drug uptake throughout the cell experiment.
Immunofluorescent staining is applied to visualize cell morphology and expressed proteins at high magnification, to evaluate for instance cell shape, target detection or changes in pathological markers upon molecule exposure.

Protein and cytokine secretion can be measured by immunoassays or high throughput proteomics across different cellular compartments allowing the observation of changes in protein secretion following exposure to specific molecules. This enables the detection of key disease or clinical markers, as well as profiling of inflammatory responses, supporting pathway analysis, biomarker discovery, and investigations into mechanisms of action.
Gene expression analysis is possible for single cells or cell populations on the chip, e.g. to check for presence of targets, or changes in disease or inflammatory markers following exposure to specific molecules, supporting pathway analysis, biomarker discovery or investigations into mechanisms of action.

In light of the recent FDA Modernization Acts, which emphasize the integration of new approach methodologies (NAMs) and reduce reliance on animal testing and also the ban of animal testing for other sectors like the cosmetic and chemical industry, AlveoliX’s advanced in-vitro models are well-positioned to support regulatory-aligned, human-relevant preclinical strategies.
AlveoliX is one of the first companies who supported regulatory submission for IND applications with organs-on-chip data. We have a strong network of experts and stakeholders in the field. We collaborate closely with regulatory consultants to support your de-risking and preclinical strategy, ensuring that the use of complex in-vitro models aligns with current and emerging regulatory expectations.